Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526638 | 0.90 | NOS1 (0.40) | CA14CA12DGAT1SMN1; SMN2CA2 | |
| SCHEMBL275280 | 0.82 | SMN1; SMN2 (0.52) | CA14CA12SMN1; SMN2CA2CA1 | |
| SCHEMBL12281961 | 0.81 | CA14 (0.46) | CA14CA12DGAT1SMN1; SMN2CA2 | |
| SCHEMBL13613724 | 0.81 | CA14 (0.46) | CA14CA12DGAT1SMN1; SMN2CA2 | |
| SCHEMBL27357842 | 0.79 | NOS1 (0.38) | CA14CA12DGAT1CA2CA1 | |
| SCHEMBL10805452 | 0.79 | SMN1; SMN2 (0.50) | CA14CA12SMN1; SMN2CA2CA1 | |
| SCHEMBL26658220 | 0.79 | SMN1; SMN2 (0.50) | CA14CA12SMN1; SMN2CA2CA1 | |
| SCHEMBL1141948 | 0.78 | CA12 (0.35) | CA14CA12DGAT1CA2CA1 | |
| SCHEMBL1088194 | 0.78 | KMT2A (0.37) | CA14CA12DGAT1CA2CA1 | |
| SCHEMBL1721887 | 0.78 | KMT2A (0.37) | CA14CA12DGAT1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12180211-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-110913858-B | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2024-09-24 | — | — | CN | disclosed |
| US-11851433-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-3625234-B1 | HEXAHYDROPYRAZOLO [1,2-A] DIAZEPINONES AND RELATED HETEROCYCLES AS INHIBITORS OF RIP-1 KINASE | DENALI THERAPEUTICS INC (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-110383066-B | Compounds, compositions and methods | 戴纳立制药公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3552017-B1 | COMPOUNDS USEFUL AS RIPK1 INHIBITORS | DENALI THERAPEUTICS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220024938-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3552017-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190300537-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2018107060-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| CN-107226858-A | Interferon macromolecule combination IFN-PMPC preparation and its application | 清华大学 | 2017-10-03 | — | — | CN | disclosed |
| CN-106674325-A | Method of preparing interferon macromolecular combination IFN-POEGMA | 清华大学 | 2017-05-17 | — | — | CN | disclosed |
| US-8507174-B2 | Positive resist composition, pattern forming method using the composition, and compound for use in the composition | FUJIFILM CORPORATION (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-2450746-A1 | Positive resist composition and pattern forming method using the composition | Fujifilm Corporation (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20110183258-A1 | POSITIVE RESIST COMPOSITION, PATTERN FORMING METHOD USING THE COMPOSITION, AND COMPOUND FOR USE IN THE COMPOSITION | FUJIFILM CORPORATION (JP) | 2011-07-28 | — | — | US | disclosed |
| EP-2177506-A1 | POSITIVE RESIST COMPOSITION, PATTERN FORMING METHOD USING THE COMPOSITION, AND COMPOUND USED IN THE COMPOSITION | Fujifilm Corporation (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180211-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | CA14 2013/4885CA12 1914/4885DGAT1 814/4885 |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CA14 4564/4885CA12 4628/4885DGAT1 2226/4885 |
| US-20220024938-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | CA14 2013/4885CA12 1914/4885DGAT1 814/4885 |
| US-20190300537-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | CA14 2013/4885CA12 1914/4885DGAT1 814/4885 |
| US-20110183258-A1 | POSITIVE RESIST COMPOSITION, PATTERN FORMING METHOD USING THE COMPOSITION, AND COMPOUND FOR USE IN THE COMPOSITION | CROCC, ACTR2, MRE11 | CA14 1890/4885CA12 2071/4885DGAT1 1451/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CA14 4564/4885CA12 4628/4885DGAT1 2226/4885 |
| US-11851433-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | CA14 2013/4885CA12 1914/4885DGAT1 814/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | CA14 4564/4885CA12 4628/4885DGAT1 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.